The researchers identified 393 Medicare patients who were previously noncompliant with another form of colorectal cancer screening; these patients had either undergone colonoscopy more than 10 years ago or had undergone a fecal occult blood test more than one year ago. Those who tested positive after multitarget stool DNA test were encouraged to receive a diagnostic colonoscopy.
Here’s what you need to know:
1. Over the course of a year, 77 providers at the multispecialty group practice ordered 393 multitarget stool DNA tests; 88.3 percent of these patients complied with the test.
2. The multitarget stool DNA test turned up negative in 85.3 percent of patients and positive in 14.7 percent of patients; 96.1 percent of the positive patients complied with the follow-up colonoscopy recommendation.
3. Of those who underwent follow-up colonoscopy, 8.2 percent had colon cancer, 42.9 percent had advanced adenomas, 30.6 percent had non-advanced adenomas and 18.4 percent were determined to be a negative result.
The researchers concluded: “Mt-sDNA provided medical benefit to screening noncompliant Medicare population.”
More articles on gastroenterology and endoscopy:
AGA, partners a step closer to developing CME to improve IBD management
Digestive diseases led to 20.4M ambulatory surgical procedures in 2010: 5 key statistics
Is fecal transplantation effective? 3 study insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.